Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
21
08
2019
revised:
16
12
2019
accepted:
21
01
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% CI = 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI = 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.
Identifiants
pubmed: 32368717
doi: 10.1093/jncics/pkaa003
pii: pkaa003
pmc: PMC7190204
doi:
Types de publication
Journal Article
Langues
eng
Pagination
pkaa003Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180888
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180819
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
Lancet Oncol. 2013 Jul;14(8):760-8
pubmed: 23742877
Ann Acad Med Singapore. 2017 May;46(5):195-201
pubmed: 28600580
J Oncol Pract. 2018 Jan;14(1):e1-e10
pubmed: 29099678
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
PLoS One. 2015 Jan 27;10(1):e0117002
pubmed: 25625938
Lancet Oncol. 2013 Dec;14(13):1307-16
pubmed: 24211163
Int J Clin Oncol. 2013 Aug;18(4):718-23
pubmed: 22791141
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
BMC Urol. 2017 Aug 22;17(1):63
pubmed: 28830482
Lancet Oncol. 2017 Apr;18(4):473-485
pubmed: 28283282
Am Soc Clin Oncol Educ Book. 2016;35:185-98
pubmed: 27249699
Prostate Int. 2015 Jun;3(2):51-5
pubmed: 26157768
Lancet Oncol. 2015 Apr;16(4):417-25
pubmed: 25743937
J Clin Oncol. 2019 Feb 10;37(5):403-410
pubmed: 30576268
J Clin Oncol. 2013 May 10;31(14):1740-7
pubmed: 23569308
Cancer. 2005 Dec 15;104(12 Suppl):3015-24
pubmed: 16247795
J Clin Oncol. 2011 Jun 1;29(16):2191-8
pubmed: 21483004
Lancet Oncol. 2013 Aug;14(9):893-900
pubmed: 23871417
Asia Pac J Clin Oncol. 2018 Aug;14(4):347-352
pubmed: 29663669
J Clin Oncol. 2012 May 1;30(13):1534-40
pubmed: 22454414
Ann Epidemiol. 2000 Nov;10(8 Suppl):S61-67
pubmed: 11189094
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
Cancer. 2014 Apr 1;120 Suppl 7:1091-6
pubmed: 24643646
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Natl Cancer Inst. 2019 Mar 1;111(3):245-255
pubmed: 30856272